Cluster headache is a primary headache condition characterized by clusters of one-sided,
high-intensity pain attacks. The headache may be episodic or chronic. Treatment options are
limited and their effects unsatisfactory. An important nerve pathway involved in the pain
attacks has a switching station at the sphenopalatine ganglion (SPG) located in the depth of
the facial bones. SPG is a known therapy target for cluster headache. The area can be
identified on CT images, but is difficult to access due to its location. Thus, the Multiguide
navigation system has been developed to enable precise delivery of the drugs that target SPG
activity. In Trondheim, two phase 1 / Phase 2 study have been carried out using botulinum
toxin A (Botox®) against SPG in patient with chronic cluster headache and chronic migraine.
The results indicate that such a treatment strategy is safe and beneficial. The current study
is a randomized, placebo-controlled, triple-blinded study to investigate whether precise
single-injection of botulinum toxin A reduces the frequency of attacks in chronic cluster
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.